Applied Molecular Evolution

Janssen Biotech, Inc.

Alliedsignal Inc.

Other

Centocor, Inc.

Centocor Ortho Biotech Inc.

Yan Chen

David J Shealy

David M Knight

Alain Philippe Vasserot

Raymond W Sweet

Sheng-Jiun Wu

David Matthew Marquis

Jing Yang

Vedrana Stojanovic-Susulic

Bailin Liang

Eric Michael Smith

Debra Gardner

Michael W Lark

Susan H Tam

Thomas F McCarthy

Xiao-Yu R Song

Xiao-yu R Song

Eric J Rainal

Peter William Petersen

Sam Wu

Audrey Baker

Susan Tam

Anti-IL-6 antibodies and antirheumatics are useful to treat and suppress IL-6 related conditions, such as rheumatoid arthritis.

Anti-IL-6 antibody

Methods of suppressing rheumatoid arthritis using an anti-IL-6 antibody

A pen-injector device comprising an anti-IL-6 antibody with a liquid formulation have applications in diagnostic and/or therapeutic compositions, methods and devices.

Pen-injector device containing anti-IL-6 antibodies

An anti-IL-6 antibody, including isolated nucleic acids that encode at least one anti-IL-6 antibody, vectors, host cells, transgenic animals or plants, and methods of making and using thereof have applications in diagnostic and/or therapeutic compositions, methods and devices.

Anti-IL-6 antibodies, compositions, methods and uses

Anti-IL-6 antibodies

Anti-IL-6 antibodies are used to treat IL-6 related conditions, such as rheumatoid arthritis, osteoarthritis, osteolysis, aseptic loosening of orthopedic implants, systemic lupus erythematosus, cutaneous lupus erythematosus, lupus nephritis, type 2 diabetes mellitus, chronic obstructive pulmonary disease, and renal cell carcinoma.

Methods of treating conditions using anti-IL-6 antibodies

Anti-IL-6 antibody nucleic acids, vectors, host cells, transgenic animals or plants, and methods of making and using thereof have applications in diagnostic and/or therapeutic compositions, methods and devices.

Anti-IL-6 antibody nucleic acid molecules and methods

Anti-il-6 antibodies, compositions, methods and uses

The invention concerns antagonists of alphav-containing integrins which have therapeutic activity in oncology applications and methods for selecting such antagonists using a peptide which competes for alphaV-integrin binding with a known monoclonal antibody having demonstrated anti-tumor activity. The claimed peptide represents a conformational epitope or mimotope present on the ligand to which the therapeutic antibodies selectively bind.

Peptides antagonistic to an anti-angiogenic antibody and uses therefor

The present invention provides a novel, optionally surfactant-free process for controlling particle number, particle size, and/or particle size distribution. The method of the invention also significantly improves monomer to polymer conversion rates, as well as, increases the level of polymer solids which can be emulsified/dispersed in water without polymer flocculation. Specifically, the improved process provides an aqueous dispersion of up to about 48% polymer solids in water in the absence of surfactant. The resulting fluoropolymers dispersions may be used in resin and coating applications.

Method of manufacturing fluoropolymers

This invention relates to novel room temperature coalescable aqueous fluoropolymer dispersions and a process for their manufacture. These dispersions may be used in a variety of applications including high temperature thermoplastic coatings, polishes, room temperature formable paints and coatings, extrudable or injection moldable resins, and adhesives.

Room temperature coalescable aqueous fluoropolymer dispersions and

Growing community of inventors

Wayne, PA, United States of America

Yan Chen